Discover
AVBP
ArriVent BioPharma, Inc.
34.50
2 x 24.92
2 x 44.12
bid
ask
-
0.24
0.69%
2 @ 04:00 PM
34.50 +0.00 (0.00%)
| Ytd | 71.47% | |
| 1y | 65.15% |
34.34
day range
35.41
16.10
52 week range
35.83
| Open | 35.15 | Prev Close | 34.74 | Low | 34.34 | High | 35.41 | Mkt Cap | 1.61B |
| Vol | 311.82K | Avg Vol | 545.56K | EPS | -3.38 | P/E | N/A | Forward P/E | -9.86 |
| Beta | 1.42 | Short Ratio | 13.98 | Inst. Own | 95.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 30.25 | 200-d Avg | 23.96 | 1yr Est | 43.64 |
| Income Statement | |||
| Operating Expenses | 46.11M | ||
| Research and Development Expense | 37.62M | ||
| Selling, General and Administrative Expense | 8.49M | ||
| Operating Income | -46.11M | ||
| Net Income | -43.32M | ||
| Net Income Common Stock | -43.32M | ||
| Net Income Common Stock (USD) | -43.32M | ||
| Consolidated Income | -43.32M | ||
| Earnings per Basic Share | -0.96 | ||
| Earnings per Basic Share (USD) | -0.96 | ||
| Earnings per Diluted Share | -0.96 | ||
| Earning Before Interest & Taxes (EBIT) | -43.32M | ||
| Earning Before Interest & Taxes (USD) | -43.32M | ||
| Weighted Average Shares | 45.07M | ||
| Weighted Average Shares Diluted | 45.07M | ||
| Balance Sheet | |||
| Cash and Equivalents | 62.10M | ||
| Cash and Equivalents (USD) | 62.10M | ||
| Investments | 264.28M | ||
| Investments Current | 264.28M | ||
| Current Assets | 348.70M | ||
| Property, Plant & Equipment Net | 370.00K | ||
| Total Assets | 349.30M | ||
| Debt Current | 99.00K | ||
| Total Debt | 419.00K | ||
| Current Liabilities | 25.00M | ||
| Debt Non-Current | 320.00K | ||
| Total Liabilities | 25.32M | ||
| Accumulated Retained Earnings (Deficit) | -447.96M | ||
| Accumulated Other Comprehensive Income | -270.00K | ||
| Shareholders Equity | 323.98M | ||
| Shareholders Equity (USD) | 323.98M | ||
| Assets Non-Current | 595.00K | ||
| Total Debt (USD) | 419.00K | ||
| Liabilities Non-Current | 320.00K | ||
| Trade and Non-Trade Payables | 8.73M | ||
| Cash Flow | |||
| Net Cash Flow from Financing | 54.87M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 16.56M | ||
| Issuance (Purchase) of Equity Shares | 54.87M | ||
| Net Cash Flow from Investing | 3.58M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 3.58M | ||
| Net Cash Flow from Operations | -41.89M | ||
| Share Based Compensation | 5.49M | ||